SecBot SecBot

BBIO drug pipeline

BridgeBio Pharma, Inc. · 1 rated drug
$78.30
+0.2% 1-day · Nov 13
Next catalyst
Feb 4, 2027
infigratinib PDUFA date · in 80 days
Typical move on FDA news
±1.8%
1-day, median of 19 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

2 dated
  1. Feb 4, 202780d
    infigratinib
    PDUFA date · achondroplasia
  2. May 7, 2027172d
    encaleret
    PDUFA date · autosomal dominant hypocalcemia type 1 (ADH1)

Drugs

soonest catalyst first
● neutral
Impact
PhasePreclinical
Time to marketAt least 5-7 years away from potential approval, assuming successful IND filing in 2027, completion of Phase 1-3 trials, and regulatory review. The program has not yet entered human testing.

BBP-717 Updated Oct 29

What to watch

BBP-717 is too early-stage to drive near-term stock movement. The next catalyst to watch is the planned IND filing in 2027, but no specific date has been set. Investors should focus on BridgeBio's nearer-term catalysts: the BBP-418 PDUFA decision on November 27, 2026, and the commercial ramp of Attruby (acoramidis) for ATTR-CM.

Bull case
  • BBP-717 targets a large unmet need: there are no approved therapies that actively clear existing TTR amyloid deposits from the heart, only stabilizers that prevent new deposits. If successful, BBP-717 could enable disease reversal in ATTR-CM patients.
  • BridgeBio has deep expertise in ATTR-CM through its approved drug Attruby (acoramidis), giving it a strong scientific and commercial foundation for a next-generation depleter antibody.
  • The ATTR-CM market is large and growing: Attruby generated significant Q3 2026 revenue, and a depleter could address patients who already have significant amyloid burden.
Bear case
  • BBP-717 is at the preclinical stage and has not yet entered human trials; most preclinical drug candidates fail to reach the market.
  • Alexion/AstraZeneca's ALXN2220 (cliramitug/NI006), a similar amyloid-depleter antibody, is already in Phase 3 testing (DepleTTR-CM trial), giving it a multi-year head start over BBP-717.
  • BBP-717 is a small program within BridgeBio's broad pipeline; the company has many nearer-term priorities including the BBP-418 PDUFA, Attruby commercial expansion, and multiple other clinical programs, so BBP-717 is unlikely to be a near-term value driver.

Other drugs in filings and trials

no drug report yet
  • infigratinib Next: PDUFA date · Feb 4, 2027 Last: NDA filed · Oct 6, 2026
  • encaleret Next: PDUFA date · May 7, 2027 Last: Priority review · Aug 10, 2026
  • oral infigratinib Last: NDA filed · Aug 10, 2026
  • BBP-418 Last: NDA filed · Jun 30, 2026
  • ATTRUBY Last: Approval · Nov 22, 2024

Past FDA events & how the stock moved

19 events
DateDrugEvent1 day5 days
Oct 6, 2026infigratinibNDA filed+0.5%−4.3%
Oct 6, 2026infigratinibPriority review+0.5%−4.3%
Aug 10, 2026encaleretPriority review−0.9%−5.4%
Aug 10, 2026oral infigratinibNDA filed−0.9%−5.4%
Jul 22, 2026encaleretNDA filed+0.6%+1.3%
Jun 30, 2026BBP-418NDA filed+3.5%+8.8%
May 27, 2026BBP-418Priority review+1.1%−3.3%
May 27, 2026BBP-418NDA filed+1.1%−3.3%
May 12, 2026encaleretFast Track+6.1%+2.0%
May 12, 2026encaleretOrphan drug designation+6.1%+2.0%
May 12, 2026encaleretNDA filed+6.1%+2.0%
May 7, 2026BBP-418PDUFA decision−1.0%+2.3%
May 7, 2026BBP-418NDA filed−1.0%+2.3%
Feb 24, 2026BBP-418Breakthrough designation−2.0%−5.0%
Feb 12, 2026infigratinibFast Track+2.6%−7.1%
Feb 12, 2026infigratinibOrphan drug designation+2.6%−7.1%
Feb 12, 2026infigratinibBreakthrough designation+2.6%−7.1%
Oct 29, 2025infigratinibBreakthrough designation−1.8%−2.9%
Nov 22, 2024ATTRUBYApproval+17.0%+14.5%